Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIX891)

• Drug Name: GSK2292767 Drug Info
• Synonyms: GSK2292767; 1254036-66-2; GSK-2292767; 4M4E8NZ73C; Methanesulfonamide, N-[5-[4-[5-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]-, rel-; CHEMBL4434674; PI3Kdelta inhibitor GS2292767; n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide; N-(5-(4-(5-(((2R,6S)-2,6-Dimethylmorpholino)methyl)oxazol-2-yl)-1H-indazol-6-yl)-2-methoxypyridin-3-yl)methanesulfonamide; Methanesulfonamide, N-(5-(4-(5-(((2R,6S)-2,6-dimethyl-4-morpholinyl)methyl)-2-oxazolyl)-1H-indazol-6-yl)-2-methoxy-3-pyridinyl)-, rel-; N-[5-[4-[5-[[(2S,6R)-2,6-Dimethylmorpholin-4-yl]methyl]-1,3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; UNII-4M4E8NZ73C; SCHEMBL173490; C24H28N6O5S; GTPL10633; EX-A994; BCP24323; BDBM50521218; MFCD22572737; s7938; AKOS032945160; CCG-269791; compound 2 [PMID: 30532965]; compound 3 [PMID: 26301626]; AC-32649; HY-15280; CS-0003832; Q27464135; N-{5-[4-(5-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-methoxypyridin-3-yl}methanesulfonamide; rel-N-[5-[4-[5-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]methanesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 49783923
  TTD Drug ID: DMIX891

Molecule-Related Drug Atlas

Drug(s) Targeting PI3-kinase delta (PIK3CD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAY 80-6946	DMLOS5R	Follicular lymphoma	2A80	Approved	[3]
Idelalisib	DM602WT	Chronic lymphocytic leukaemia	2A82.0	Approved	[4]
Umbralisib	DMYRBO1	Follicular lymphoma	2A80	Approved	[5]
IPI-145	DMWA24P	Follicular lymphoma	2A80	Approved	[6]
Leniolisib	DMWAD93	Stomach cancer	2B72	Approved	[7]
Buparlisib	DM1WEHC	Breast cancer	2C60-2C65	Phase 3	[8]
INCB50465	DMZJP2T	Diffuse large B-cell lymphoma	2A81	Phase 2	[9]
ME-401	DMK0UOY	Follicular lymphoma	2A80	Phase 2	[9]
RP6530	DMYILGK	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[9]
Parsaclisib	DMYBIFS	Follicular lymphoma	2A80	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PI3-kinase delta (PIK3CD)	TTGBPJE	PK3CD_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03045887) A Single-centre, Double-blind (Sponsor Open), Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 as a Dry Powder in Healthy Participants Who Smoke Cigarettes. U.S.National Institutes of Health.
• [2] Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase delta Inhibitor. J Pharmacol Exp Ther. 2019 Jun;369(3):443-453.
• [3] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [6] PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
• [7] Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
• [8] Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.